Monteverde & Associates PC and Kahn Swick & Foti, LLC Announce Proposed Class Action Settlement on Behalf of Holders of Revance Therapeutics, Inc. Common Stock

Barchart · 22h ago

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- 

TO:

 ALL RECORD HOLDERS AND ALL BENEFICIAL HOLDERS OF REVANCE THERAPEUTICS, INC. ("REVANCE" OR THE "COMPANY") COMMON STOCK WHO HELD SUCH STOCK AS OF THE FEBRUARY 6, 2025 CLOSING OF THE MERGER BETWEEN REVANCE AND CROWN LABORATORIES, INC. ("CROWN") (THE "MERGER") AND (i) HAD YOUR SHARES EXCHANGED FOR $3.65 PER SHARE IN CONNECTION WITH THE CLOSING OF THE MERGER (ON FEBRUARY 6, 2025), AND (ii) ACQUIRED YOUR SHARES EITHER (A) PRIOR TO FEBRUARY 29, 2024, OR (B) BETWEEN FEBRUARY 29, 2024 AND FEBRUARY 6, 2025, BUT ARE NOT ELIGIBLE TO RECEIVE COMPENSATION AS TO SOME OR ALL OF THOSE SHARES PURSUANT TO THE SETTLEMENT IN THE CONSOLIDATED SECURITIES CLASS ACTION STYLED IN RE REVANCE THERAPEUTICS, INC. SECURITIES LITIGATION, CASE NO. 3:25-CV-0018-EJR (M.D. TENN.)

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.